Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Finished Goods (2016 - 2025)

Corcept Therapeutics' Finished Goods history spans 10 years, with the latest figure at $9.4 million for Q4 2025.

  • For Q4 2025, Finished Goods rose 14.7% year-over-year to $9.4 million; the TTM value through Dec 2025 reached $9.4 million, up 14.7%, while the annual FY2025 figure was $9.4 million, 14.7% up from the prior year.
  • Finished Goods for Q4 2025 was $9.4 million at Corcept Therapeutics, up from $8.6 million in the prior quarter.
  • Across five years, Finished Goods topped out at $9.4 million in Q4 2025 and bottomed at $4.9 million in Q3 2021.
  • The 5-year median for Finished Goods is $7.6 million (2023), against an average of $7.3 million.
  • The largest annual shift saw Finished Goods decreased 25.09% in 2021 before it soared 48.95% in 2023.
  • A 5-year view of Finished Goods shows it stood at $6.5 million in 2021, then skyrocketed by 41.6% to $9.2 million in 2022, then fell by 15.9% to $7.7 million in 2023, then rose by 6.01% to $8.2 million in 2024, then increased by 14.7% to $9.4 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Finished Goods are $9.4 million (Q4 2025), $8.6 million (Q3 2025), and $6.7 million (Q2 2025).